Skip to main content
ConductScienceScienceDex

Gary Fanger

NIH Rank #3582
Unclaimed recordClaim profile
  • Early Career
  • Diverse Portfolio

Researcher identity and coverage

Current affiliation
Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
NIH RePORTER identity
Profile ID 14958505Search this ID in NIH RePORTER
ScienceDex PI coverage
FY2024 through FY2025Career claims are limited to the years shown.Metrics use this researcher's latest loaded PI award year; ScienceDex is current through FY2026.

NIH Funding · FY2025

Linked Award Amount
$2.9M
Full award amounts, FY2025
Award Records
4
Records listing this PI
Award-Linked Rank
#3,582
By linked amount among FY2025 PIs
Earliest Year Loaded
2024
ScienceDex PI coverage

One scientist record

NIH portfolios and SHARE

This is the common ScienceDex page for Gary Fanger. NIH portfolio memberships are contextual views of this scientist, while SHARE Score, S-Index, and S-Impact describe the researcher's global sharing track record.

Review metric definitions

FY2025 NIH portfolio memberships

No institute-level portfolio release is available for this scientist and fiscal year yet. Existing award history remains unchanged above.

Researcher-associated datasets

These datasets are linked to this researcher's ShareScore identity. This does not by itself prove that an NIH portfolio funded each dataset.

No compatible author-to-dataset release is published. Dataset records are unavailable, not zero.

Award-linked funding history

Linked NIH award amounts and rank by fiscal year.

FY2025 award records by amount

NIH award records listing Gary Fanger as a PI. Multi-PI records show the full award amount for context.

  • 5R44AG084484-03R44
    A Novel Immunological-Directed Biotherapy for Treating Rheumatoid Arthritis
    Rise Therapeutics, Llc
    $953K
    award amount
  • 5R44AI174844-03R44
    A Novel Immunological-Directed Synthetic Biology-Based Drug for the Treatment of Multiple Sclerosis
    Rise Therapeutics, Llc
    $827.7K
    award amount
  • 5SB1DK141356-02SB1
    A Novel Synthetically Engineered Oral Immunotherapy for Treating Ulcerative Colitis
    Rise Therapeutics, Llc
    $704.6K
    award amount
  • 1UG3DE034134-01A1UG3
    A Novel Immunological-Directed Probiotic for the Treatment of Sjögren’s Syndrome
    Rise Therapeutics, Llc
    $429.2K
    award amount

Award organization

Organizations that administered FY2025 awards listing Gary Fanger as a PI.

FY2025 award administered by Rise Therapeutics, Llc (MD).

Coverage and award-record milestones

Computed from the fiscal years currently available in ScienceDex.

  1. 2024
    First NIH Award
    Rise Therapeutics, Llc
  2. 2024
    $500K Cumulative Funding
  3. 2024
    $1M Cumulative Funding
  4. 2024
    $2M Cumulative Funding
  5. 2024
    $5M Cumulative Funding
  6. 2024
    Entered Top 50% Nationally
    Ranked #918
  7. 2024
    Entered Top 25% Nationally
    Ranked #918
  8. 2024
    Entered Top 10% Nationally
    Ranked #918
  9. 2024
    Entered Top 5% Nationally
    Ranked #918

Shared-award investigators

Other investigators listed on at least one of the same NIH award records as Gary Fanger.

Christian Furlan Freguia
Rise Therapeutics, LLC
3
shared awards
Christian Furlan Freguia
Rise Therapeutics, Llc
1
shared award
Sathyanarayana Janardhanan
Rise Therapeutics, Llc
1
shared award
Sathyanarayana Janardhanan
Rise Therapeutics, LLC
1
shared award

Explore further

Find collaborators for Gary Fanger

Search NIH-funded principal investigators by topic, department, or activity.

Open Find Collaborators →

Benchmark grant budgets

Compare median NIH grant budgets across departments, mechanisms, and years.

Open Grant Budget Benchmark →